论文部分内容阅读
采用重组技术,通过一种设计和构建方法可研制出人类抗体。作者应用V基因噬菌体显示技术,研制出了一种针对HPA-1a的人类单链可变功能区抗体片段(scFv),这种scFv预防多克隆抗-HPA-1a与血小板结合,阻断了母亲的抗-HPA-1a对胎儿血小板的破坏。为了研制一种有治疗作用的抗体,作者用RhD/抗-D模型设计了一个显性基因,该基因编码一种不能结合经典Fc受体的IgG和Clq。为了完成这个工作,作者以IgG2的脯氨酸/缬氨酸/丙氨酸替换残基233-235,通过IgG4的甘氨酸和丝氨酸/丝氨酸替换残基327和330/331,在IgG支架上应用定向的位点引起突变。用抗-D Fog-1的V基因重组这种变异的稳定区。研制出的这种IgG抗-D抗体不能触发
Using recombinant techniques, human antibodies can be developed through a design and construction approach. Using V gene phage display technology, the authors developed a human single chain variable domain antibody fragment (scFv) against HPA-1a that prevents polyclonal anti-HPA-1a binding to platelets and blocks mothers Of anti-HPA-1a destruction of fetal platelets. To develop a therapeutic antibody, the authors designed a dominant gene using the RhD / anti-D model, which encodes an IgG and Clq that does not bind to the classical Fc receptor. To accomplish this work, the authors replaced residues 233-235 with proline / valine / alanine of IgG2, residues 327 and 330/331 with glycine and serine / serine of IgG4, and orientation on an IgG scaffold The site of mutation causes. The stable region of this variation was recombined with the V gene of anti-D Fog-1. This IgG anti-D antibody developed can not be triggered